Just a decade ago, during the financial crisis, the life sciences sector, dominated by small-molecule pharmaceuticals, was being squeezed.
On the one hand, pharma was finding it harder to identify small-molecule targets and match them with candidate drugs. On the other, it was meeting the challenge of generic competition to the ‘blockbuster’ drugs that had driven the market in the previous decade.
Paul outlines the recent changes in the life sciences sector, including the advance of technology and the implication for patents.
Read the full version originally published in the October edition of Intellectual Property Magazine (subscription required).
